ArticleExpert opinion on biological therapy2011
miRNA-based therapies for the irritable bowel syndrome.
Article in Expert opinion on biological therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research states and trends of micro RNA in irritable bowel syndrome: a bibliometric analysis.Clinical and experimental medicine · 2024Pooled it
- MiR-26b-3p Promotes Intestinal Motility Disorder by Targeting FZD10 to Inhibit GSK3β/β-Catenin Signaling and Induce Enteric Glial Cell Apoptosis.Molecular neurobiology · 2024Article
- Catechol-O-Methyltransferase Loss Drives Cell-Specific Nociceptive Signaling via the Enteric Catechol-O-Methyltransferase/microRNA-155/Tumor Necrosis Factor α Axis.Gastroenterology · 2023Article
- Functional Implications and Clinical Potential of MicroRNAs in Irritable Bowel Syndrome: A Concise Review.Digestive diseases and sciences · 2023Review
- Role of microRNAs in Disorders of Gut-Brain Interactions: Clinical Insights and Therapeutic Alternatives.Journal of personalized medicine · 2021Review
- Micro-organic basis of functional gastrointestinal (GI) disorders: Role of microRNAs in GI pacemaking cells.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- Histone H3K9 methylation regulates chronic stress and IL-6-induced colon epithelial permeability and visceral pain.Neurogastroenterology and motility · 2020Article
- Article
- MicroRNA-200a Targets Cannabinoid Receptor 1 and Serotonin Transporter to Increase Visceral Hyperalgesia in Diarrhea-predominant Irritable Bowel Syndrome Rats.Journal of neurogastroenterology and motility · 2018Article
- Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform.Journal of visualized experiments : JoVE · 2016Article
- Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions.American journal of physiology. Gastrointestinal and liver physiology · 2016Review
- Article
- MicroRNA expression profiles differentiate chronic pain condition subtypes.Translational research : the journal of laboratory and clinical medicine · 2015Article
- The Relationship Between Colonic Macrophages and MicroRNA-128 in the Pathogenesis of Slow Transit Constipation.Digestive diseases and sciences · 2015Article
- Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system.Gastroenterology · 2015Article
- MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability.Gastroenterology · 2015Article
- Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome.Experimental and molecular pathology · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The irritable bowel syndrome (IBS) is a common disorder of unknown etiology. Recently, a group of dysregulated microRNAs (miRNAs) in blood microvesicles and in colon tissue have been identified in IBS patients. miRNAs have been shown to modulate specific biological processes such as differentiation, proliferation, apoptosis and metabolism. The ideal strategy would be to use specific miRNAs as both diagnostic and therapeutic tools to recover intestinal function and treat intractable gastrointestinal symptoms. In conclusion, further study of the functional role of miRNAs will lead to a better understanding of the dysregulation of intestinal pathways in IBS patients. The results may lead to preventive and/or therapeutic strategies that use small molecules (such as mimics or inhibitors of specific miRNAs) to affect genetic and epigenetic control. Future clinical trials may use microvesicle-associated miRNA-based therapies by using specific inhibitors/mimics of miRNA to target gene expression and treat IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.